The United Nations Single Convention of 1961 placed cannabis in Schedule IV, the most restrictive classification in the international drug control architecture, on the basis that it was a substance of no medical value and high abuse potential. At the time of that classification, the endocannabinoid system had not been discovered, THC had not been isolated, and the precise chemical profile of the plant had not been characterised. The scientific knowledge required to make an informed assessment of the plant's medical value did not yet exist. The classification was made without it. In the sixty-five years since that classification, researchers have identified more than 100 distinct cannabinoid compounds in the plant, documented hundreds of terpenes, characterised the precise receptor mechanisms through which each class of compound operates, and obtained regulatory approval in the world's most stringent pharmaceutical systems for medicines derived directly from Cannabis sativa L. The classification has not been revised to reflect any of this. The Meridian Science Desk reviews the complete chemical profile of the plant the law says has no medical value.

glandular trichomes cannabis biochemical factory phytocannabinoids terpenes chemical synthesis plant biology

The cannabis plant's chemical complexity is produced in its glandular trichomes: microscopic, hair-like structures that cover the surface of the plant's flowers and upper leaves and that function as a highly specialised biochemical factory. Under a microscope, the trichomes resemble tiny mushrooms: a thin stalk topped by a spherical gland filled with resin. It is within this resin that the plant concentrates its cannabinoids and terpenes. The density and activity of the trichomes vary across cannabis varieties and growing conditions, which accounts for the significant variation in chemical profile between different cannabis strains and preparations.

The trichomes synthesise cannabinoids through a biosynthetic pathway that begins with a precursor molecule called cannabigerolic acid (CBGA), commonly referred to as the mother cannabinoid. CBGA is converted by specific plant enzymes into the three primary cannabinoid lines: THCA (the acidic precursor to THC), CBDA (the acidic precursor to CBD), and CBCA (the acidic precursor to CBC). When the plant is dried and cured, or when the plant material is exposed to heat (a process called decarboxylation), the acidic forms lose a carboxyl group and become the active cannabinoids: THC, CBD, and CBC respectively. This biosynthetic understanding is not incidental. It means that the plant's chemistry is a coherent, structured system, not a random collection of compounds, and that the relationships between compounds are biologically determined and pharmacologically significant.

THC CBD primary cannabinoids CB1 CB2 receptors mechanism action psychoactive non-intoxicating allosteric modulator

The distinction between THC and CBD is one of the most important and most misunderstood aspects of cannabis pharmacology. The psychoactive properties of cannabis are attributable primarily to THC. CBD does not produce them. This means that the blanket classification of cannabis as a psychoactive narcotic, used to justify its inclusion in the most restrictive scheduling category alongside heroin, conflates two chemically and pharmacologically distinct compounds that happen to occur in the same plant. It is the equivalent of classifying the opium poppy alongside coffee on the basis that both plants produce compounds that affect the central nervous system.

CBG CBN THCV minor cannabinoids cannabis therapeutic applications diabetic neuropathy MRSA antibacterial

Beyond THC and CBD lies a spectrum of minor cannabinoids, synthesised in smaller quantities but possessing highly targeted therapeutic mechanisms. Three are of particular significance.

Cannabigerol (CBG) is the non-intoxicating precursor from which THC and CBD are ultimately synthesised. As the plant matures, most CBG is converted to other cannabinoids, leaving relatively small concentrations in mature plants. The CBG that remains has documented antibacterial properties, including activity against methicillin-resistant Staphylococcus aureus (MRSA), one of the most clinically dangerous antibiotic-resistant pathogens in the world. CBG also exhibits neuroprotective properties and is being studied for its capacity to reduce intraocular pressure, which is directly relevant to the treatment of glaucoma.

Cannabinol (CBN) is formed when THC degrades through oxidation, which is why aged cannabis has higher CBN concentrations than fresh material. CBN is mildly psychoactive but significantly less so than THC. It is currently the subject of active research for its sedative properties and its antibacterial activity, including against MRSA strains that are resistant to multiple conventional antibiotics. The potential of a plant-derived compound to address the global antibiotic resistance crisis is not a fringe claim. It is the subject of peer-reviewed investigation in mainstream pharmacology journals.

Tetrahydrocannabivarin (THCV) is, for the Mauritian context, the most urgently relevant of the minor cannabinoids. THCV is a structural analogue of THC but at low doses it acts as a CB1 antagonist rather than an agonist, producing effects opposite to those of THC in the metabolic domain. Clinical research demonstrates that THCV decreases appetite, increases satiety, and up-regulates energy metabolism. Systematic reviews of randomised controlled trials confirm that cannabinoid-based interventions provide statistically significant, clinically meaningful pain relief for diabetic peripheral neuropathy, a condition that afflicts a substantial proportion of the diabetic population and for which conventional pharmaceutical options are frequently inadequate or poorly tolerated.

The relevance to Mauritius is not peripheral. One in five Mauritians is diabetic. Diabetic peripheral neuropathy, the nerve damage caused by chronically elevated blood glucose, is one of the most painful and refractory conditions in the Mauritian health system. Whilst the state spends substantial sums importing synthetic pharmaceuticals to manage the symptoms of diabetic nerve degeneration, it criminalises a botanical compound actively being studied globally for glycaemic control and neuropathy. The Dangerous Drugs Act 2000 does not make an exception for THCV. It does not ask whether the cannabinoid is psychoactive. It does not ask whether it kills anyone. It classifies the entire plant, and every compound within it, as a dangerous drug.

terpenes entourage effect Ben-Shabat Mechoulam 1998 myrcene linalool pinene limonene cannabis whole plant medicine

Cannabinoids do not operate in isolation within the plant. Cannabis also produces hundreds of volatile aromatic compounds called terpenes, which govern its distinctive scent and offer documented therapeutic benefits independent of the cannabinoids. The four most extensively studied cannabis terpenes and their demonstrated pharmacological actions are as follows.

Terpene	Aromatic Profile	Demonstrated Therapeutic Action
Myrcene	Earthy, musky, herbal	Analgesic, anti-inflammatory, sedative. The most abundant terpene in most cannabis varieties. Facilitates the passage of cannabinoids across the blood-brain barrier.
Linalool	Floral, lavender	Anxiolytic, anticonvulsant, sleep aid. Also the primary terpene in lavender, which has an established evidence base in anxiety research. Documented to modulate GABA receptor activity.
Pinene	Pine, fir, fresh	Bronchodilator, anti-inflammatory, memory retention aid. Alpha-pinene has been shown to counteract some of the short-term memory effects of THC by inhibiting acetylcholinesterase.
Limonene	Citrus, lemon	Antidepressant, immune system stimulant, antifungal. Widely studied in oncology research for its antiproliferative properties in breast and colon cancer cell lines.

In 1998, researchers Shimon Ben-Shabat and Raphael Mechoulam published a paper coining the term "entourage effect". This foundational concept in cannabinoid science proposes that the physiological effect of the whole plant is greater than the sum of its isolated parts. Functionally inactive compounds and secondary terpenes potentiate the biological activity of primary cannabinoids by preventing their enzymatic degradation or by modulating their binding affinity at receptors. The anxiety sometimes triggered by pure THC, for instance, is substantially mitigated by the presence of CBD and the relaxing terpene linalool. The entourage effect is the scientific basis for the clinical observation that whole-plant cannabis preparations frequently outperform isolated synthetic cannabinoids in therapeutic settings.

The entourage effect also has a direct political implication. The pharmaceutical model for drug development involves identifying a single active compound, isolating it, and patenting it. A whole plant cannot be patented. The entourage effect is the scientific evidence that this pharmaceutical model is, for cannabis, pharmacologically suboptimal. Isolating a single compound and removing it from its natural synergistic context may make it patentable and profitable, but the scientific evidence suggests it makes it less therapeutically effective. The pharmaceutical industry's commercial interest and the patient's therapeutic interest point in opposite directions. The Dangerous Drugs Act 2000 enforces the pharmaceutical industry's preference by criminalising the whole plant that the science says works better.

Epidiolex FDA approval June 2018 CBD cannabis Dravet Lennox-Gastaut epilepsy New England Journal Medicine clinical trial

The most irrefutable evidence against the "no medical value" classification comes from the United States Food and Drug Administration, the most stringent pharmaceutical regulatory body in the world. On 25 June 2018, the FDA approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older. In 2020, the approval was extended to tuberous sclerosis complex. Epidiolex is not a synthetic cannabinoid analogue. It is a highly purified, plant-derived liquid formulation of CBD, extracted directly from Cannabis sativa L.

The approval was based on rigorous, double-blind, placebo-controlled Phase 3 clinical trials published in the New England Journal of Medicine, one of the most respected medical journals in the world. The trials demonstrated a statistically significant reduction in convulsive seizure frequency compared with placebo. The European Medicines Agency followed with its approval in September 2019, under the name Epidyolex.

The significance of the Epidiolex approval cannot be overstated. The premier pharmaceutical regulatory body in the world approved a medicine derived directly from Cannabis sativa L. for use in children as young as one year old. The same plant that the UN Single Convention of 1961 classified as having no medical value, the same plant that the Dangerous Drugs Act 2000 classified as a dangerous drug without medical exception, was approved by the FDA as a paediatric medicine forty-seven years after the UN said it had no medical value. The Mauritian government has not updated its legislative position to reflect this fact.

cannabis no medical value claim demolished 100 cannabinoids Schedule IV UN Single Convention FDA approval scientific evidence

The scientific literature on the chemical profile of cannabis is clear, verified, and incontestable. From the retrograde signalling of the endocannabinoid system to the targeted efficacy of THCV for diabetic neuropathy, from the antibacterial properties of CBG against MRSA to the FDA-approved paediatric epilepsy medicine derived directly from the plant, the evidence assembled across sixty years of pharmacological research points consistently in one direction. Cannabis sativa L. is a plant of extraordinary and diverse pharmacological complexity whose therapeutic applications span neurology, immunology, metabolic medicine, and oncology.

To continue classifying cannabis alongside heroin as a substance devoid of medical utility is not a matter of scientific caution. It is an active, structural denial of biological reality. The Dangerous Drugs Act 2000 does not cite the scientific literature in its justification. It does not engage with the endocannabinoid system. It does not distinguish between THC and CBD, between psychoactive and non-psychoactive compounds, between the plant and the chemical compounds within it. It criminalises all of them, without exception, on the basis of a classification made in 1961 before the science existed to assess it. That classification was wrong in 1961. It has become more wrong with each decade of research since. The Meridian has documented the evidence. The evidence speaks for itself.

This is the sixth article in The Colonised Plant: The Cannabis Edition, June 2026, and the third in Chapter Two: The Science. The next article documents the record that has never been broken: zero deaths from cannabis overdose in all of recorded human history, and what that record means when placed alongside the documented mortality of every other substance that remains legal. The complete edition is published at themeridian.info/june-2026.